Table 1. Characteristics of included studies.
| Author (year) | Country | Sample size | Age (yrs) | Tumor stage | Cyclophosphamide arm | Control arm | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number | Molecular type | Regimen | Number | Molecular type | Regimen | ||||||
| Jackisch 2002, (12) | Germany | 369 | 24–77 | T2-3; N0-2; M0 | 178 | Not reported | AC-DOC: doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2 I.V. every 21 days for 4 cycles, then docetaxel 100 mg/m2 I.V. every 21 days for 4 cycles | 191 | Not reported | ddAT: doxorubicin 50 mg/m2, docetaxel 75 mg/m2 I.V. every 14 days for 4 cycles | |
| von Minckwitz 2005, (13) | Germany | 904 | 24–77 | T2-3; N0-2; M0 | 453 | ER+: 315; PR+: 250 | AC-DOC: doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2 every 21 days for 4 cycles, then docetaxel 100 mg/m2 every 21 days for 4 cycles | 451 | ER+: 295; PR+: 279 | ADOC: doxorubicin 50 mg/m2, docetaxel 75 mg/m2 every 14 days for 4 cycles | |
| Hong 2013, (14) | Korea | 84 | 26–69 | T1-4 | 47 | ER+: 26; PR+: 21; HER2+: 14 | AC-T: adriamycin 50 mg/m2, cyclophosphamide 500 mg/m2 for 4 cycles, then paclitaxel 175 mg/m2 at a 3-week interval for 4 cycles | 37 | ER+: 22; PR+: 23; HER2+: 10 | AD: adriamycin 50 mg/m2, docetaxel 75 mg/m2 at a 3-week interval for 6 cycles | |
| Schneeweiss 2019, (15) | Germany | 945 | 21–76 | T1c-T4a-d | 470 | ER+ or PR+: 207; HER2+: 192; TRBC: 200 | iddEPC: epirubicin 150 mg/ m2 every 2 weeks (q2w) for 3 cycles, then paclitaxel 225 mg/m2 q2w for 3 cycles, then cyclophosphamide 2000 mg/m2 q2w for 3 cycles | 475 | ER+ or PR+: 219; HER2+: 190; TRBC: 203 | PM (Cb): paclitaxel 80 mg/m2 weekly, non-pegylated liposomal doxorubicin 20 mg/m2 weekly. For TNBC, additional carboplatin AUC 1.5 weekly for 18 weeks | |
yrs, years; ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; TNBC, triple-negative breast cancer; I.V., intravenous injection; AC-DOC, doxorubicin + cyclophosphamide + docetaxel; ddAT, dose-dense doxorubicin + docetaxel; ADOC, doxorubicin + docetaxel; AC-T, adriamycin + cyclophosphamide + paclitaxel; AD, adriamycin + docetaxel; iddEPC, intense dose-dense epirubicin + paclitaxel + cyclophosphamide; PM, paclitaxel + non-pegylated liposomal doxorubicin; Cb, carboplatin, AUC, area under curve.